Aaron Brooks, DO
Pulmonary Disease · Pensacola, FLNPI 1740775980
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,500 of the $3,764 with a category attached, or 66.4%. Intuitive Surgical accounts for 68.7% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $3,028, more than ten times the $58 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 53 payments — averaging $71.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$201
- Actelion Pharmaceuticals US, Inc.$141
- Abbott$131
- GSK$100
- Pfizer$69
- plus $536 from 19 others
What the payments were for
- Food & beverage$1,26434%
- Education$2,50066%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $2,585 |
| AstraZeneca | 5 | $201 |
| Actelion Pharmaceuticals US, Inc. | 2 | $141 |
| Abbott | 1 | $131 |
| GSK | 6 | $100 |
| Pfizer | 5 | $69 |
| Insmed, Inc. | 2 | $50 |
| Vapotherm Inc | 2 | $45 |
| Novo Nordisk | 3 | $45 |
| Electromed, Inc. | 4 | $43 |
| Novartis | 2 | $42 |
| Merck | 2 | $38 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $36 |
| Verona Pharma, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Abiomed | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Resmed Corp | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $15 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,500
- FreeStyle Libre Pro$131
- BREZTRI$125
- UPTRAVI$113
- OPSUMIT$113
How this compares
$3,764 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $52,731 |
| NucalaMepolizumab | 12 | $46,082 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $23,656 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $10,563 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $9,963 |
| Tiotropium Bromide | 15 | $5,864 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $5,366 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,204 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,155 |
| Montelukast Sodium | 25 | $277 |
| Prednisone | 17 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala | $100 | $98,81290 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $201 | $33,61867 claims |
| Boehringer IngelheimStiolto Respimat | $17 | $10,56317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Pensacola
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.